Since osimertinib is a selective inhibitor of mutated EGFR in tumor cells and spares wild type EGFR expressed mainly in host cells, the feasibility of a transient combination of IGF-1R inhibitor with osimertinib may be more superior to first or second generation EGFR-TKIs. Here, IGF1R is linked to neoplasm.